Researchers say the new immunotherapy drugs can target two types of evasive cancer-driving proteins

Scientific research has shown that new immunotherapy drugs can target two types of evasive cancer-driving proteins.
Share on twitter
Share on facebook
Share on digg
Share on pocket
Share on telegram
Share on reddit
Share on pinterest
Share on linkedin
Share on whatsapp
Share on stumbleupon
Share on twitter
Share on facebook
Share on digg
Share on pocket
Share on telegram
Share on reddit
Share on pinterest
Share on linkedin
Share on whatsapp
Share on stumbleupon

Scientific research has revealed that new immunotherapy drugs can target two evasive cancer-driving proteins. Through research in mice, it has been found that designer antibodies can stop the growth of tumours by targeting two proteins that are cancer’s most infamous offenders, the RAS and p53.

Researchers have known these proteins to mutate in many tumours and have defied most other drug development efforts. Researchers hope the new findings will hold up in clinical trials as the drugs could allow for the possibility of helping the immune system fight off hard-to-treat cancers such as ovarian and pancreatic.

ORIGINAL SOURCE

MORE QUICK NEWS

Leave a Reply

Your email address will not be published. Required fields are marked *

Passion for the Truth. Compassion for People.

Facts, Logic and Reasoning guide our process

We strive to challenge our own bias through an open sourced platform.

We search for the inner connection between all people aiming to bridge divides.